https://gc7inhibitor.com/solut....ion-interleukin-6-in
These findings provide a rationale to vaccinate against mosquito saliva rather than the pathogen itself. To the knowledge, no vector salivary protein-based vaccine is tested for safety and immunogenicity in humans. We aimed to assess the safety and immunogenicity of Anopheles gambiae saliva vaccine (AGS-v), a peptide-based vaccine derived from four A gambiae salivary proteins, in humans. Practices In this randomised, placebo-controlled, double-blind, phase 1 t
Like
Comment
Share
